Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment...
News
Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate
Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among...
New data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with...
Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress
– Data demonstrates Notable’s PPMP potential in selecting more active investigational pre-hematopoietic stem cell therapy drug combinations, as compared to...
SS Innovations International Presents at MoneyShow Virtual Expo
“The Progression of Surgical Robotics: Introducing the SSi Mantra System” Video Presentation Now Available for Viewing FORT LAUDERDALE, FL, June...
Inspire Medical Systems, Inc. Announces FDA Approval for Apnea Hypopnea Index Indication Expansion and Increased Body Mass Index Labeling
MINNEAPOLIS, June 09, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 – a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy – in Climacteric, the Journal of the International Menopause Society
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced...
Colorado Governor Jared Polis Named Opening Speaker for Psychedelic Science 2023
Governor Polis to kick off the world's largest gathering of the psychedelic ecosystem in DenverDENVER, June 09, 2023 (GLOBE NEWSWIRE)...
Crinetics to Highlight Broad Pipeline at ENDO 2023
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for EntrepreneurshipSAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE)...
Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
Patients transplanted with trem-cel achieved primary neutrophil engraftment and high levels of myeloid donor chimerism.Strong investigator enthusiasm and continued robust...
Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
CLEVELAND, June 09, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received feedback from the...
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICMLLAUSANNE,...
Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
SAN CARLOS, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel...
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bitopertinPatients...
Finch Announces Reverse Stock Split of Common Stock
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a...
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
Phase 3 program to include one parallel group study and one randomized withdrawal study mADL11 as primary endpoint Single 60...
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 28th Annual Congress of the European Hematology Association
Keros Therapeutics will be hosting a conference call and webcast today, June 9, 2023, at 8:00 a.m. Eastern time, to...
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Extraordinary General Meeting of Infant Bacterial Therapeutics
At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB (publ) on June 9, 2023, it was resolved to approve...